Navigation Links
Conatus Pharmaceuticals Appoints Anthony W. Fox, MD, Ph.D., as Chief Medical Officer
Date:3/25/2008

SAN DIEGO, March 25 /PRNewswire/ -- Conatus Pharmaceuticals Inc. today announced the appointment of Anthony "Tony" W. Fox as part-time Chief Medical Officer to oversee the recently initiated Phase 2 clinical trial of CTS-1027 in Hepatitis C virus-infected patients as well as assisting in the development of the longer-term clinical development plans.

Tony is a pharmaceutical physician with more than 20 years in the industry. Previous industrial positions have been at Procter and Gamble, Glaxo Inc. (Imitrex (R), Ultiva(R), Amerge(R)), and with small companies. Formerly, Tony was President of the whole of EBD Group, and continues now as President of EBD Consulting Inc., (Carlsbad, CA, and Munich, Germany). Among his current professional affiliations are the American College of Clinical Pharmacology, the American Society of Pharmacology and Experimental Therapeutics, and the Society of Apothecaries of London. He is a Fellow of the Institute of Biology and the Royal College of Physicians, as well as of the latter's Faculty of Pharmaceutical Medicine. Tony's numerous publications span industrial, pharmacological, regulatory, and experimental medicine areas. He co-edits "Principles and Practice of Pharmaceutical Medicine" (John Wiley and Son, second edition), which is a major international textbook in its field.

"Tony fills a critical position at Conatus," said Steven J. Mento, Ph.D., President and CEO, of Conatus. "He brings significant scientific and management experience and will be of strategic value as Conatus moves forward with the development of drug candidates to treat diseases such as hepatitis where abnormal inflammation plays a key role."

"This was an opportunity to focus on translating a well-known biological mechanism, with a well-characterized phase 2 compound, into a truly innovative area of medicine. It was also an invitation to join a team whom I already knew to be really sound, and has already achieved hard endpoints," said Dr.
'/>"/>

SOURCE Conatus Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... GoDaddy, IX Web Hosting and Bluehost are ... Server) hosting, which is the method of partitioning ... of which has the appearance and capabilities of ... recently compared many professional web hosting suppliers and ... VPS hosting suppliers in the global market. , ...
(Date:8/31/2014)... Mesa, Arizona (PRWEB) August 31, 2014 For ... ragweed is likely the culprit. Ragweed is the most common ... percent of Americans. , The most common symptoms of ragweed ... and throat, and sneezing. Ragweed allergy can also lead to ... ragweed allergies should consult an allergist about allergy immunotherapy - ...
(Date:8/31/2014)... 01, 2014 In order to celebrate the ... announced its latest designs and launched a big promotion. Now, ... , All the company’s new cars are made with ... for the global customers. As a matter of fact, it ... items. Those who are in need of cheap cars can ...
(Date:8/31/2014)... LabDoor.com tests the purity and label accuracy of ... website, “We buy products in the same fashion as ... sites. No manufacturer-supplied samples are permitted at LabDoor.” As ... a recent study was performed on twenty of the ... States for Vitamin D3 content, heavy metal contamination, and ...
(Date:8/31/2014)... 2014 In the wake of growing ... proposed legislation to require mandatory labeling of GMOs on ... purchasing decisions that affect their own health and the ... for stringent measures to eliminate GMOs from dietary supplements, ... Engagement” (I.C.E.) initiative with the objective of advancing the ...
Breaking Medicine News(10 mins):Health News:GoDaddy, IX Web Hosting and Bluehost Are Awarded As Hosting Experts by Top10BestSEOHosting.com 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 2Health News:AllergyEasy Announces Success Helping Patients Build Immunity To Autumn Ragweed Pollens With Under-the-tongue Drops 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 2Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 3Health News:#1 Rank Awarded to NutriGold’s Vitamin D3 Gold Supplement for the "Best Value" in Vitamin D 4Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 2Health News:NutriGold Announces its I.C.E. Initiative to Educate Consumers about GMOs in Dietary Supplements 3
... , , ... Reportlinker.com announces that a new market research report is available ... Endoscopy Devices , , http://www.reportlinker.com/p0131252/Gastrointestinal-Endoscopy-Devices.html ... market for Gastrointestinal Endoscopy Devices in Millions of US$ analyzed by ...
... , Rx Bottles Filled with ... Fix Broken System Upon His Return to Washington ... Members of Congress have just returned to Washington D.C. after their ... to make reforming health care a top priority. With a giant ...
... Economic slump encourages more people ... Vancouver, ... more Canadians are making the decision to head back to school to re-train, instead of waiting ... Canada, has seen a dramatic spike in enrollments in 2009. Between July 2008 and July 2009, ...
... , , ... San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a ... National Institute of Allergy and Infectious Disease (National Institutes of Health) ... H5N1 Avian influenza. , , "We thank ...
... ECCO 15 ESMO 34 will take place at ... D-14055 Berlin, Germany ( www.icc-berlin.de ) from Sunday 20 ... be more than 2,000 presentations and over 15,000 participants ... congress to date. The congress will discuss the ...
... , ATLANTA, Sept. 8 Renowned ... Coke, in collaboration with the American Dietetic Association (ADA) are providing ... Tastefully campaign will feature pop-up kitchens in midtown Manhattan and Boston, ... are all a part of living well. , , ...
Cached Medicine News:Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 2Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 3Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 4Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 5Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 6Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 7Health News:Reportlinker Adds Gastrointestinal Endoscopy Devices Report 8Health News:Fall 2009 Sees Spike in Enrollments at CDI College 2Health News:Vaxart Awarded NIH Grant to Support Development of Orally-Delivered H5N1 Avian Influenza Vaccine 2Health News:Media registration for ECCO 15 -- ESMO 34 multidisciplinary cancer congress 2Health News:Media registration for ECCO 15 -- ESMO 34 multidisciplinary cancer congress 3Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 2Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 3Health News:Video: Eat Tastefully Campaign: Diet Coke, Renowned Chef, Pop-Up Kitchen Reveal Secrets to Great Taste, Living Well 4
(Date:8/29/2014)... 2014 According to a ... Extraction type (SFE, Cold Pressed, Organic Solvent, & Others), ... Food Supplements, Fragrance, & Others) - Global Trends & ... segments the Amaranth Seed Oil Market with an ... terms of value. The Amaranth Seed Oil Market ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... Research and Development Trend Forecast of Pharmaceutical Equipment ... analyzes China,s pharmaceutical equipment industry ... demand, competition landscape, and business performance of domestic major ...
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
Breaking Medicine Technology:Amaranth Seed Oil Market worth $700.6 Million by 2019 2Amaranth Seed Oil Market worth $700.6 Million by 2019 3Amaranth Seed Oil Market worth $700.6 Million by 2019 4Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2
... 5, 2011 Today Scios Inc. announced an agreement with ... misbranding of NATRECOR® (nesiritide), a prescription medication for patients with ... Scios Inc. entered a guilty plea to a single misdemeanor ... to pay an $85 million fine. Scios acknowledges ...
... Puma Biotechnology, Inc., a development stage biopharmaceutical company, ... the worldwide commercial rights to neratinib, a potent, ... through the epidermal growth factor receptors, ErbB1 (EGFR), ... being studied in the neoadjuvant, adjuvant and metastatic ...
Cached Medicine Technology:Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 2Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 3Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 4Puma Biotechnology Announces Licensing Agreement with Pfizer for the Development and Commercialization of Neratinib, an Investigational Pan-HER Inhibitor; Closes $55 Million Private Placement and Completes Merger 5